BioSpace News Archive

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2022 before the U.S. financial market opens on August 11, 2022.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2022 before market open on Tuesday, August 2nd , 2022.

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced today that ILUVIEN ® data will be overviewed in various scientific abstracts at the American Society of Retina Specialists (ASRS) conference being held in New York, New York from July 13-16.

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, announced today that John Tucker, president & chief executive officer, is scheduled to participate in the Late-Stage Advancements in Heart Failure Therapeutics and Management panel discussion.

The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), has awarded grants of approximately $50,000 each to five community-based organizations (CBOs) as recipients of the inaugural Access to Care Empowerment for Sickle Cell (ACE) Grant Program.

Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, announced favorable topline results from its recently completed SEQURUS-1 study.

Oncocyte Corporation (Nasdaq: OCX) today announced that it has completed development and clinical validation of the Laboratory Test for its newly-branded VitaGraft™ Transplant Monitoring tests for Liver and Kidney, entering a $2B US market.

On July 11, 2022, VenusP-ValveTM, Venus Medtech’s in-house developed innovative transcatheter pulmonic valve replacement system, was approved by China’s National Medical Products Administration for the treatment of severe pulmonary regurgitation in patients after congenital heart defects procedure with native right ventricular outflow tract.

Xilis, Inc., a pioneering biotechnology company developing its MicroOrganoSphere™ (MOS™) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, has closed an extension of over US$19 million to its Series A financing round, bringing the total amount raised to over US$89 million.

Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8006, an antibody drug conjugate (ADC) that targets folic acid receptor α (FRα).